Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023.
西雅图,2023年10月31日(环球网)--领先的单分子蛋白质组分析平台公司鹦鹉螺生物技术公司(纳斯达克:NAUT;或“Nautilus”)今天公布了截至2023年9月30日的第三季度财务业绩。
"I'm very pleased with the progress Nautilus made in Q3 as we continue our drive towards commercial readiness", said Sujal Patel, CEO of Nautilus. "Continuing to increase the scale and robustness of the platform remains a key area of focus as we ready the platform for launch next year. With an increasing focus on proteomics by the scientific community, moves by major life science companies to expand their proteomics-related offerings, and massive international investments in the study of proteins, it is clear to me that a strong foundation has been laid for the 'proteomics era' of biology and medicine to take root and flourish. I believe that our continued exceptional financial discipline and business execution, combined with a platform designed to establish a new gold standard for proteomic analysis, positions us well for both short-term and longer-term success."
“我对Nautilus在第三季度取得的进展感到非常高兴,因为我们继续推动商业准备,”Nautilus首席执行官Sujal Patel说。随着我们为明年推出该平台做准备,继续增加该平台的规模和稳定性仍然是一个关键的重点领域。随着科学界对蛋白质组学的日益关注,各大生命科学公司扩大其蛋白质组学相关产品的举措,以及对蛋白质研究的大规模国际投资,我清楚地看到,生物学和医学的“蛋白质组学时代”已经为其扎根和蓬勃发展奠定了坚实的基础。我相信,我们持续出众的财务纪律和业务执行,再加上一个旨在建立蛋白质组分析新黄金标准的平台,使我们为短期和长期的成功奠定了良好的基础。“
Third Quarter 2023 Financial Results
第三季度2023年财务业绩
Operating expenses were $19.1 million for the third quarter of 2023, a 21% increase from $15.8 million for the three months ended September 30, 2022. The increase in operating expenses was driven primarily by an increase in headcount to support ongoing development of our products.
2023年第三季度的运营费用为1910万美元,比截至2022年9月30日的三个月的1580万美元增长了21%。运营费用的增加主要是由于为支持我们产品的持续开发而增加的员工人数。
Net loss was $15.9 million for the third quarter of 2023, as compared to a net loss of $14.1 million for the corresponding prior year period.
2023年第三季度净亏损为1,590万美元,而上年同期净亏损为1,410万美元。
Cash, cash equivalents, and investments were $275.7 million as of September 30, 2023.
截至2023年9月30日,现金、现金等价物和投资为2.757亿美元。
Webcast and Conference Call Information
网络广播和电话会议信息
Nautilus will host a conference call to discuss the third quarter 2023 financial results, business developments and outlook before market open on Wednesday, October 31, 2023 at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio.
Nautilus将在2023年10月31日(星期三)太平洋时间上午5:30/东部时间上午8:30市场开盘前主持电话会议,讨论2023年第三季度的财务业绩、业务发展和前景。网络直播的现场音频将在该公司网站的“投资者”栏目中播放,网址为:Www.nautilus.bio。
About Nautilus Biotechnology, Inc.
鹦鹉螺生物技术公司简介
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Nautilus公司总部设在华盛顿州西雅图,研发总部设在加利福尼亚州圣卡洛斯,是一家处于发展阶段的生命科学公司,致力于创建一种量化和解锁蛋白质组复杂性的平台技术。Nautilus的使命是通过使获得蛋白质组的途径民主化并使人类健康和医学取得根本性进展来改变蛋白质组学领域。欲了解更多有关鹦鹉螺的信息,请访问www.nautilus.bio。
Special Note Regarding Forward-Looking Statements
关于前瞻性陈述的特别说明
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus' expectations regarding the company's business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the timing of the launch of Nautilus' product platform and full commercial availability, the functionality and performance of Nautilus' product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus' products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus' assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus' product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus' scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption "Risk Factors" in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2023 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
本新闻稿包含符合联邦证券法的前瞻性陈述。本新闻稿中的前瞻性陈述包括但不限于有关Nautilus对公司业务运营、财务业绩和经营结果的预期;对任何收入时间或预测的预期;对推出Nautilus产品平台和完全商业可用性的时间的预期;Nautilus产品平台的功能和性能;其在提供蛋白质组访问、药物开发和药物发现、扩大研究视野和实现科学探索和发现方面的潜在影响;以及新兴蛋白质组学技术的当前和未来能力和限制。这些陈述基于对Nautilus产品、目标市场以及其他当前和新兴蛋白质组学技术的发展的大量假设,涉及大量风险、不确定性和其他因素,可能会导致实际结果与这些前瞻性陈述中明示或暗示的信息大不相同。可能对Nautilus假设的准确性及其实现本新闻稿中陈述的前瞻性陈述的能力产生重大影响的风险和不确定性包括(但不限于)以下内容:Nautilus的产品平台尚未投入商业使用,仍在进行重大的科学和技术开发,这本身就具有挑战性,难以预测,特别是对于像Nautilus正在开发的那些高度新颖和复杂的产品。即使我们的开发努力是成功的,我们的产品平台也需要对其在生命科学研究中的功能性和实用性进行实质性的验证。在Nautilus的科学和技术开发以及相关产品验证和商业化的过程中,我们可能会遇到因意外事件而导致的重大延误。我们不能就我们的开发、合作和商业化计划的结果或与其相关的时间表提供任何保证或保证。有关鹦鹉螺及其发展努力面临的其他风险和不确定性的更详细描述,投资者应参考我们的年度报告中“风险因素”标题下的信息,以及我们将提交给美国证券交易委员会的截至2023年9月30日的季度报告和其他报告中的信息。本新闻稿中的前瞻性陈述是截至本新闻稿发布之日的。除非适用法律另有要求,否则Nautilus不承担更新任何前瞻性陈述的责任。因此,您不应依赖这些前瞻性陈述作为我们截至本新闻稿发布日期之后的任何日期的观点。
Disclosure Information
披露信息
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Nautilus使用提交给美国证券交易委员会的文件、其网站(www.nautilus.bio)、新闻稿、公开电话会议、公共网络广播和其社交媒体账户作为披露重大非公开信息和遵守FD法规的手段。因此,Nautilus鼓励投资者、媒体和其他对Nautilus感兴趣的人审查它在这些地点公布的信息,因为这些信息可能被视为重要信息。
Media Contact
press@nautilus.bio
媒体联系人
邮箱:Press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
投资者联系方式
邮箱:Investorrelationsnautilus.bio
Nautilus Biotechnology, Inc.
Condensed Consolidated Balance Sheets
As of September 30, 2023 and December 31, 2022 (Unaudited)
鹦鹉螺生物技术公司
简明综合资产负债表
截至2023年9月30日和2022年12月31日(未经审计)
(in thousands, except share and per share amounts) |
September 30, 2023 |
December 31, 2022 |
|||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 74,104 | $ | 114,523 | |||
Short-term investments | 109,185 | 69,948 | |||||
Prepaid expenses and other current assets | 3,499 | 2,738 | |||||
Total current assets | 186,788 | 187,209 | |||||
Property and equipment, net | 4,283 | 3,700 | |||||
Operating lease right-of-use assets | 33,669 | 28,866 | |||||
Long-term investments | 92,439 | 129,169 | |||||
Other long-term assets | 1,157 | 1,108 | |||||
Total assets | $ | 318,336 | $ | 350,052 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 1,142 | $ | 1,272 | |||
Accrued expenses and other liabilities | 4,285 | 3,528 | |||||
Current portion of operating lease liability | 3,467 | 1,991 | |||||
Total current liabilities | 8,894 | 6,791 | |||||
Operating lease liability, net of current portion | 32,169 | 28,337 | |||||
Total liabilities | 41,063 | 35,128 | |||||
Stockholders' equity: | |||||||
Preferred stock | — | — | |||||
Common stock | 12 | 12 | |||||
Additional paid-in capital | 464,509 | 455,330 | |||||
Accumulated other comprehensive loss | (2,033 | ) | (1,854 | ) | |||
Accumulated deficit | (185,215 | ) | (138,564 | ) | |||
Total stockholders' equity | 277,273 | 314,924 | |||||
Total liabilities and stockholders' equity | $ | 318,336 | $ | 350,052 |
(单位为千,不包括每股和每股金额) |
9月30日, 2023年 |
十二月三十一日, 2022 |
|||||
资产 | |||||||
流动资产: | |||||||
现金和现金等价物 | $ | 74,104 | $ | 114,523 | |||
短期投资 | 109,185 | 69,948 | |||||
预付费用和其他流动资产 | 3499 | 2738 | |||||
流动资产总额 | 186,788 | 187,209 | |||||
财产和设备,净额 | 4,283 | 3700 | |||||
经营性租赁使用权资产 | 33,669 | 28,866 | |||||
长期投资 | 92,439 | 129,169 | |||||
其他长期资产 | 1,157 | 1108 | |||||
总资产 | $ | 318,336 | $ | 350,052 | |||
负债与股东权益 | |||||||
流动负债: | |||||||
应付帐款 | $ | 1142 | $ | 1,272 | |||
应计费用和其他负债 | 4,285 | 3528 | |||||
经营租赁负债的当期部分 | 3467 | 1991 | |||||
流动负债总额 | 8894 | 6791 | |||||
经营租赁负债,扣除当期部分 | 32,169 | 28,337 | |||||
总负债 | 41,063 | 35,128 | |||||
股东权益: | |||||||
优先股 | - | - | |||||
普通股 | 12 | 12 | |||||
额外实收资本 | 464,509 | 455,330 | |||||
累计其他综合损失 | (2,033 | ) | (1,854 | ) | |||
累计赤字 | (185,215 | ) | (138,564 | ) | |||
股东权益总额 | 277,273 | 314,924 | |||||
总负债和股东权益 | $ | 318,336 | $ | 350,052 |
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Operations
Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited)
鹦鹉螺生物技术公司
简明综合业务报表
截至2023年9月30日和2022年9月30日的三个月和九个月(未经审计)
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
(in thousands, except share and per share amounts) | 2023 | 2022 | 2023 | 2022 | |||||||||||
Operating expenses | |||||||||||||||
Research and development | $ | 11,996 | $ | 9,571 | $ | 34,785 | $ | 28,085 | |||||||
General and administrative | 7,079 | 6,249 | 21,366 | 19,229 | |||||||||||
Total operating expenses | 19,075 | 15,820 | 56,151 | 47,314 | |||||||||||
Other income (expense), net | 3,197 | 1,757 | 9,500 | 2,799 | |||||||||||
Net loss | $ | (15,878 | ) | $ | (14,063 | ) | $ | (46,651 | ) | $ | (44,515 | ) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.13 | ) | $ | (0.11 | ) | $ | (0.37 | ) | $ | (0.36 | ) | |||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 124,933,837 | 124,651,318 | 124,896,975 | 124,522,164 |
截至9月30日的三个月, | 截至9月30日的9个月, | ||||||||||||||
(单位为千,不包括每股和每股金额) | 2023年 | 2022 | 2023年 | 2022 | |||||||||||
运营费用 | |||||||||||||||
研发 | $ | 11,996 | $ | 9571 | $ | 34,785 | $ | 28,085 | |||||||
一般和行政 | 7079 | 6249 | 21,366 | 19,229 | |||||||||||
总运营费用 | 19,075 | 15,820 | 56,151 | 47,314 | |||||||||||
其他收入(费用),净额 | 3,197 | 1,757 | 9,500 | 2799 | |||||||||||
净亏损 | $ | (15,878 | ) | $ | (14,063 | ) | $ | (46,651 | ) | $ | (44,515 | ) | |||
普通股股东应占每股基本亏损和稀释后每股净亏损 | $ | (0.13 | ) | $ | (0.11) | ) | $ | (0.37 | ) | $ | (0.36 | ) | |||
加权平均股数,用于计算普通股股东应占每股净亏损,包括基本亏损和稀释亏损 | 124,933,837 | 124,651,318 | 124,896,975 | 124,522,164 |
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Cash Flows
Nine Months Ended September 30, 2023 and 2022 (Unaudited)
鹦鹉螺生物技术公司
现金流量表简明合并报表
截至2023年9月30日和2022年9月30日的9个月(未经审计)
Nine Months Ended September 30, | |||||||
(in thousands) | 2023 | 2022 | |||||
Cash flows from operating activities | |||||||
Net loss | $ | (46,651 | ) | $ | (44,515 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities | |||||||
Depreciation | 1,294 | 871 | |||||
Stock-based compensation | 9,064 | 7,547 | |||||
Amortization (accretion) of premium (discount) on securities, net | (2,040 | ) | (340 | ) | |||
Amortization of operating lease right-of-use assets | 2,821 | 1,624 | |||||
Changes in operating assets and liabilities: | |||||||
Prepaid expenses and other assets | (878 | ) | 239 | ||||
Accounts payable | 22 | (850 | ) | ||||
Accrued expenses and other liabilities | 757 | 860 | |||||
Operating lease liabilities | (2,200 | ) | (865 | ) | |||
Net cash used in operating activities | (37,811 | ) | (35,429 | ) | |||
Cash flows from investing activities | |||||||
Proceeds from maturities of securities | 51,249 | 142,075 | |||||
Purchases of securities | (51,895 | ) | (101,665 | ) | |||
Purchases of property and equipment | (2,029 | ) | (2,095 | ) | |||
Net cash (used in) provided by investing activities | (2,675 | ) | 38,315 | ||||
Cash flows from financing activities | |||||||
Proceeds from exercise of stock options | 23 | 274 | |||||
Proceeds from issuance of common stock under employee stock purchase plan | 92 | 153 | |||||
Net cash provided by financing activities | 115 | 427 | |||||
Net (decrease) increase in cash, cash equivalents and restricted cash | (40,371 | ) | 3,313 | ||||
Cash, cash equivalents and restricted cash at beginning of period | 115,477 | 186,461 | |||||
Cash, cash equivalents and restricted cash at end of period | $ | 75,106 | $ | 189,774 |
截至9月30日的9个月, | |||||||
(单位:千) | 2023年 | 2022 | |||||
经营活动的现金流 | |||||||
净亏损 | $ | (46,651 | ) | $ | (44,515 | ) | |
对净亏损与经营活动中使用的现金净额进行的调整 | |||||||
折旧 | 1,294 | 871 | |||||
基于股票的薪酬 | 9,064 | 7547 | |||||
证券溢价(折价)摊销(递增)净额 | (2,040 | ) | (340) | ) | |||
经营性租赁使用权资产摊销 | 2821 | 1,624 | |||||
经营性资产和负债变动情况: | |||||||
预付费用和其他资产 | (878) | ) | 二百三十九 | ||||
应付帐款 | 22 | (850) | ) | ||||
应计费用和其他负债 | 七百五十七 | 八百六十 | |||||
经营租赁负债 | (2,200 | ) | (865) | ) | |||
用于经营活动的现金净额 | (37,811 | ) | (35,429 | ) | |||
投资活动产生的现金流 | |||||||
证券到期日收益 | 51,249 | 142,075 | |||||
购买证券 | (51,895) | ) | (101,665 | ) | |||
购置财产和设备 | (2,029 | ) | (2,095 | ) | |||
投资活动提供的现金净额(用于) | (2,675 | ) | 38,315 | ||||
融资活动产生的现金流 | |||||||
行使股票期权所得收益 | 23个 | 二百七十四 | |||||
根据员工购股计划发行普通股所得款项 | 92 | 153 | |||||
融资活动提供的现金净额 | 一百一十五 | 427 | |||||
现金、现金等价物和限制性现金净(减)增 | (40,371 | ) | 3313 | ||||
期初现金、现金等价物和限制性现金 | 115,477 | 186,461 | |||||
期末现金、现金等价物和限制性现金 | $ | 75,106 | $ | 189,774 |